Chromatography
From Discovery to Production of Active Biotherapeutic and Pharmaceutical Ingredients
Jun 19 2018
Kromasil fits across the entire biotherapeutic and pharmaceutical organisations. Typically, researchers carry out method development using Kromasil UHPLC and HPLC columns based on 1.8 - 5 μm particle sizes. Then scientists and engineers in discovery, process and manufacturing departments scale the method up according to their needs using the same Kromasil stationary phases in prepacked columns and bulk ranging from 7 to 25 μm. This Kromasil capability to supply the entire development and production path of an API is unique in the market and shortens the timeline plus minimises costs when producing a drug. With 30 years of experience, Kromasil continues to expand its list of products, provides ready-made columns as well as bulk material for normal phase, reversed phase, chiral, HILIC, SFC and SMB chromatography.
For more information go to www.kromasil.com.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark
Aug 28 2024 Phnom Penh, Cambodia
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK